Maralixibat Chloride
FDA-approved product (solution, oral), marketed as Livmarli.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alagille syndrome
- Pruritus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for bile therapy
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Maralixibat Chloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174 · start 2023-01-16
Registered record
- Registry ID
- NCT05543174
- Conditions
- Alagille Syndrome (ALGS)
- Interventions
- TAK-625
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2023-01-16
- Completion
- 2025-07-25
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlagille Syndrome (ALGS)InterventionTAK-625PhasePhase 3Registry statusCompletedA Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT05543187 · start 2023-01-10
Registered record
- Registry ID
- NCT05543187
- Conditions
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Interventions
- TAK-625
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2023-01-10
- Completion
- 2025-07-22
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProgressive Familial Intrahepatic Cholestasis (PFIC)InterventionTAK-625PhasePhase 3Registry statusCompletedA Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
NCT04729751 · start 2021-09-09
Registered record
- Registry ID
- NCT04729751
- Conditions
- Progressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease
- Interventions
- Maralixibat
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-09-09
- Completion
- 2024-12-17
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProgressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver DiseaseInterventionMaralixibatPhasePhase 2Registry statusCompletedMRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
NCT04168385 · start 2020-01-16
Registered record
- Registry ID
- NCT04168385
- Conditions
- Cholestatic Liver Disease
- Interventions
- Maralixibat
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-01-16
- Completion
- 2024-09-04
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholestatic Liver DiseaseInterventionMaralixibatPhasePhase 2Registry statusCompletedSafety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
NCT02160782 · start 2014-10-28
Registered record
- Registry ID
- NCT02160782
- Conditions
- Alagille Syndrome
- Interventions
- LUM001 (Maralixibat); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-10-28
- Completion
- 2020-05-28
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlagille SyndromeInterventionLUM001 (Maralixibat); PlaceboPhasePhase 2Registry statusCompleted